Copyright © Inderes 2011 - present. All rights reserved.

Scandion Oncology

0.012

 

SEK

 

-18.42 %

Less than 1K followers

SCOL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.

Read more
Market cap
2.91M SEK
Turnover
22.17K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
28/8
2025

Interim report Q2'25

11/11
2025

Business review Q3'25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.